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Abstract 
 
Synthesis of Cyclo and Backbone Extended Nucleosides 
Yiran Li 
Advisor: Prof. Larry W. McLaughlin 
 
Nucleic acids are essential biological molecules that encode and transfer 
genetic information from generation to generation. Intensive efforts have been made 
by scientists to study the properties of nucleic acids, looking for opportunities that 
could help diagnose, prevent, and cure disease, and/or gain a greater insight into the 
wonder of nature. 
Chapter 2 presents our synthetic attempts towards the rigidified nucleosides 
2’-deoxy-6,3’-propanouridine and 2’-deoxy-6,3’-butanouridine. These nucleosides are 
constrained so that they mimic the native conformation in DNA duplex and are 
postulated to increase duplex stability, as well as increase the affinity of the 
nucleobase for its complementary partner. 
Chapter 3 presents work towards the synthesis of backbone extended 
nucleosides. These molecules have the potential to form a new type of helical 
structure when incorporated into a double helix. Through the investigation of these 
novel nucleic acids, we would like to gain a greater understanding of the properties 
that contribute to duplex stability. 
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1.1 Biological Importance of DNA and RNA 
Nucleic acids, including DNA and RNA, are the carriers of genetic information 
of life. DNA is responsible for the storage of most genetic information. In the process 
of replication, a double-strand of DNA first unwound by DNA helicase, then each 
strand is used as a template, while the complimentary strand is synthesized by DNA 
polymerase from the 5’ to 3’ direction.1 This process makes exact duplicates of DNAs 
with only a low possibility of mutations. Thus, genetic information is passed on from 
generation to generation, and mutations, although rare, may contribute to the 
evolution of life. 
On the other hand, RNA can also be the storage of genetic information in viruses 
and regulate various life events as ribozymes.2,3 RNA’s primary role in biological 
system is to translate DNA into proteins. Similar to the process of replication, genetic 
information is transmitted from DNA to mRNA (massager RNA) through 
transcription. Using one strand of DNA as the template, RNA polymerase synthesizes 
a complimentary strand of RNA that carries the genetic information out of the 
nucleus. 
 
Figure 1.1 Schematic diagram of transcription. Figure adopted from Voet.4 
Once associated with the ribosome, the information in each mRNA is further 
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translated into protein with the assistance of small tRNAs (transfer RNAs). Each 
tRNA is coded by three nucleotides (anticodon), and is attached to a specific amino 
acid. While the three nucleotides pair with their partners on the mRNA (codon) by 
sequence, the amino acids are linked together, forming a peptide with a corresponding 
sequence. With further folding and regulation, a mature protein is produced, which 
then regulates the behavior of a biological system. 
 
1.2 Nucleic Acid Structures 
1.2.1 Bases, nucleosides and nucleotides 
Nucleic acids are linear linkages of monomers called nucleotides. A nucleotide 
consists of three parts (Figure 1.2): one of the five heterocyclic bases (Figure 1.3), a 
pucker-shaped pentose sugar, either ribose for RNA or deoxyribose for DNA, and a 
phosphate group.5 A nucleoside contains only the nucleobase and pentose sugar. 
 
Figure 1.2 Components of DNA and RNA 
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The nucleobases recognize their specific pairing partners by forming hydrogen 
bonds which form in the center of double helix. The purine bases, adenine (A) and 
guanine (G), and the pyrimidine base cytosine (C) are found in both DNA and RNA. 
Thymidine (T) is only found in DNA and uracil (U) only exist in RNA (Figure 1.3). 
The nucleobases are linked to pentose sugars which are further linked together 
through phosphodiester linkages. The sugar and phosphate group together forms the 
backbone of nucleic acid.  
 
Figure 1.3 Structure of the five nucleobases 
In order to address nucleic acid structure more conveniently, the numbering 
scheme of nucleosides is illustrated in Figure 1.4. Positions on the pentose sugar are 
distinguished from nucleobases by a prime symbol. 
 
Figure 1.4 Numbering scheme illustrated for thymidine and 2’-deoxyadenosine. 
 
1.2.2 Torsion angles and sugar puckering 
The detailed conformation of a nucleic acid is defined by torsion angles (Figure 
1.5). The torsion angle χ for the glycosidic bond is important because it defines the 
orientation of the nucleobase. The two main orientations are called syn and anti. In 
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anti-conformation, the bulky part of the base points away from the sugar ring while in 
syn-conformation, it points towards the sugar ring (Figure 1.6). Because of the steric 
interactions between sugar ring and the base, anti is the predominant conformation in 
nucleosides. However, when the 8 position of purine or 6 position of pyrimidine is 
substituted with bulky groups, the steric effect is reversed, and the syn-conformation 
becomes favorable through rotation around the glycosidic bond.6 Change of hydration 
conditions, salt concentrations and enzymatic activities can also change the 
orientation of nucleobases.7 
 
Figure 1.5 Torsion angles of nucleotide. Image adopted from Saenger.8  
 
Figure 1.6 Base orientation of 2’-deoxyadenosine and 2’-deoxythymidine. 
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Another important structural feature of each nucleotide is the puckering mode of 
the pentose sugar. A co-planar sugar conformation is apparently not energetically 
favorable. The sugar twists out of plane into an envelope form or twisted form in 
order to minimize the non-bonding interactions between its substitutes (Figure 1.7). 
The puckering is described by identifying the major displacement of C2’ and C3’ from 
the plane of C1’-O4’-C4’. The term “endo” dictates when an atom is twisted to the 
same side as C5’ and the nucleobase, while “exo” defines the opposite side. For 
example, when the endo displacement of C3’ is greater than the exo displacement of 
C2’, this ribose conformation is called C3’-endo (Figure 1.7 e). 
 
Figure 1.7 Sugar puckering modes. a. Co-planar sugar ring. b. C3’-endo envelope.  
c. C2’-endo envelope. d,e. 3’-endo twisted form. Image adopted form Seanger.8 
In different types of DNA, sugar puckering adopts different conformations. In an 
A-form helix, the sugar tends to adopt the C3’-endo conformation, while in a B-form 
helix, it tends to adopt the C2’-endo conformation. This intrinsic difference further 
influences the overall shape of the double helix. Furthermore, other sugar puckering 
conformations such as O4’-endo and C1’-exo, have also been found to exist under 
certain condition.9 
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1.2.3 Hydrogen bonding and base pairing 
The mutual recognition of nucleobase A by T and G by C through specific 
hydrogen bonding interaction is crucial for DNA transcription and translation. The 
NH groups on the base are good hydrogen bond donors, while the sp2 hybridized 
electron pairs on the oxygen of base C=O groups are much better hydrogen bond 
accepters than the oxygen on the phosphate group or on the pentose sugar. The 
specific arrangements of hydrogen bond donors and accepters and the geometric 
constrains of each base only allow it to form base pairs with specific bases containing 
complimentary hydrogen bond donors and accepters. The A-T and G-C Watson-Crick 
base pairs were first discovered in 1953.10 A-T base pairs form two hydrogen bonds, 
while G-C base pairs form three hydrogen bonds, making G-C pairs stronger than A-T 
(Figure 1.8). The geometry of the hydrogen bonds brings two nucleotides on 
complimentary strands together and gives approximately the same C1’-C1’ distance 
and same angle between the two glycosidic bonds. As a result, the four base pair 
combinations: A-T, T-A, C-G, G-C, produce a duplex DNA structure which varies 
very little with its sequence.  
Although Watson-Crick base pairs are the predominant form found in DNA 
duplexes, other types of base pairs also exist. For example, wobble base pairs are not 
normally found in standard duplexes, but they play an important role in the structure 
of transfer RNA.11,12 Many wobble pairs on tRNA use an inosine nucleotide, which is 
not found in chromosomal DNA. Inosine can bind C through Watson-Crick base 
pairing and U or A through wobble base pairing (Figure 1.8).13,14 Hoogsteen base 
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pairs also occur when the purine base is rotated into the syn conformation.15 Other 
non-Watson-Crick base pairs include GC reverse Watson-Crick base pairs,16 C+C,17 
A+C,18 A+A,19 and so on. 
 
Figure 1.8 Base pairs in nucleic acids 
 
1.2.4 DNA double helix 
The primary structure of DNA is a sequence of nucleosides linked together by 
phosphate groups, and the secondary structure of DNA forms a duplex under native 
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conditions. Common conformations of A-DNA, B-DNA and Z-DNA were discovered 
and the structures have been carefully studied. As we addressed above, one intrinsic 
structural difference of A-DNA and B-DNA is the sugar puckering mode. Sugars 
adopt C3’-endo conformation in A-DNA and C2’-endo in B-DNA. Crystal structure 
showed that with a C3’-endo sugar, the distance between adjacent phosphate groups is 
about 5.9 Å，while in C2’-endo, the distance is extended to 7.0 Å.  
The right-handed B-DNA is most commonly observed in nature. The bases are 
held in an anti-conformation and form Watson-Crick base pairs. The base pairs sit in 
the center of the helix and are nearly perpendicular to the helix axis. The sugar 
phosphate backbone winds around the base pairs, and form a major and a minor 
groove (Figure 1.9). An ideal B-form helix has 10 base pairs per turn, a helical twist 
of 36° per base pair, a pitch of 34 Å, and a 23.7 Å diameter. Relatively speaking, 
B-DNA features a wide and deep major groove and a narrow minor groove (Figure 
1.9). 
 
Figure 1.9 Structures of A-DNA, B-DNA and Z-DNA. Image adopted from Voet.4  
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Under dehydration conditions, B-DNA can be transformed to A-DNA. This form 
also maintains a right-handed double helical structure and the base pair patterns and 
glycosidic bond arrangements are the same as B-DNA.20 However, A-DNA is wider 
and has a more compact structure. A-DNA has 11 base pairs per turn, a pitch of 34 Å, 
and a larger diameter of 26 Å. The base pairs are tilted and displaced away from the 
helical axis towards the minor groove; creating hollow center (Figure 1.10). Moreover, 
A-DNA feathers a deep and narrow major groove, and a wide and shallow minor 
groove. 
 
Figure 1.10 Top views of A-DNA, B-DNA and Z-DNA. Image adopted from Voet.4 
Z-DNA with a left-handed helical structure was first discovered by Andrew 
Wang.19 It is only observed in DNA with certain sequences poly (dGC) – poly (dGC) 
and poly (dAC) – poly (d GT) under highly dehydration conditions. Z-DNA has 12 
base pairs per turn and a pitch of 45 Å. The left handed helix results from the 
alternating syn, anti-conformation of nucleobases along the helical axis. Z-DNA is not 
very stable and it appears as a transient duplex that is usually induced by other 
biological activities.21-23 
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1.3 Factors Affecting Duplex Stability 
Noncovalent interactions arise via a number of different mechanisms; including 
Van der Wall’s interactions, hydrogen bonding and ionic interactions. These kinds of 
interactions are intrinsically weak (on the scale of 5 kcal/mol) compared to covalent 
bonds (bond energies of 90-100 kcal/mol). However, noncovalent interactions play an 
important role in stabilizing the secondary structure of DNA. The three main forces 
that affect the stability of a DNA duplex have been well studied: the interactions in 
plane with the base due to hydrogen bonding, the interactions perpendicular to the 
base planes stabilized by London dispersion forces and hydrophobic effects, and the 
ionic interactions mainly caused by the negatively charged phosphate groups. 
 
1.3.1 Hydrogen bonding 
Hydrogen bonds are mainly electrostatic in nature. X - H··· Y is formed when the 
hydrogen atom is connected to two atoms X and Y with a higher electronegativity. 
Hydrogen bonds between the nucleobases in DNA are of the type N - H·· N, and N - 
H··· O. They are about 20-30 times weaker than covalent bonds and are more 
susceptible to bending and stretching.  
The formation of hydrogen bonds has a cooperative effect. When a hydrogen 
bond is formed, the charges on the atoms involved are changed due to polarization. H 
becomes more electropositive and X and Y become more electronegative. This effect 
increases the affinity of X and Y for the formation of more hydrogen bonds (Figure 
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1.11). At least two cyclic N - H···N or N - H··· O hydrogen bonds must form in order 
to produce a stable base pair. 
 
Figure 1.11 Cooperative effect of hydrogen bonding. The hydrogen in base pairs can jump in 
a concerted mechanism from the donor of one base to the accepter of the partner base.  
Image adopted from Sanger.8 
Many efforts have been made by scientists to study the energy contribution of 
hydrogen bonding in duplex formation, which requires comparison studies of base 
pairs that differ only in the number of hydrogen bonds. The energy difference between 
two-hydrogen-bond base pairs and three-hydrogen-bond base pairs has been 
investigated.24 Comparing the energy difference of I-C base pairs and G-C base pairs 
reveals that the third hydrogen bond has a free energy of -0.7 to -1.6 kcal/mol. 
However, the energy study of the stacked G-C pairs indicated that three base pairs 
contribute less than three times this amount because of the cooperative effect. 
 
1.3.2 Base stacking 
Base stacking is the dominant factor that holds the double helix together.25,26 It is 
composed of several different noncovalent forces: London dispersion forces, 
  13 
 
hydrophobic interaction, and the π-π electrostatic interactions between adjacent base 
pairs.27,28 Base stacking gets stronger as the nucleic acid chain increase in length.29 
Futhermore, different base pairs contribute differently to base stacking forces: 
purine-purine > pyrimidine-purine > pyrimidine-pyrimidine. It is worth noting that in 
order to maximize both hydrogen bonding and base stacking, nucleobases can adjust 
their position within the duplex with tilt, roll, twist and propeller twist (Figure 1.12).  
 
Figure 1.12 Conformational adjustment of nucleobase to maximize hydrogen bonding and 
base stacking interactions. Image adopted from Sanger.8 
Oligonucleotides exhibit a strong UV absorption at approximately 260nm. As 
shown in figure 1.13, the UV absorption is significantly lowered with base stacking. 
The phenomenon, known as hypochromicity is extremely useful in measuring the 
stability of nucleic acids. When the UV absorption is measured as a function of 
temperature, the resulting plot is the melting curve. With the elevation of temperature, 
DNA unwinds and base stacking is interrupted. As a result, an increase in UV 
absorption is observed. The temperature at the midpoint of the increase of absorption 
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is defined as melting temperature (Tm), which is used to illustrate the stability of DNA 
duplex. 
 
Figure 1.13 UV absorption of DNA double helix (1), random coil DNA (2), and unstacked 
nucleotides of the same concentration as in native DNA. Image adopted from Sanger.8 
 
1.3.3 Ionic interactions 
At physiological pH, the phosphate group in the DNA backbone carries a 
negative charge. This charge must be neutralized in order to avoid electrostatic 
repulsion, and form stable duplexes. Cations such as magnesium and lithium 
neutralize the negative charge and enhance duplex stability.30,31 In general, divalent 
cations provide more stabilization than monovalent cations. The ability for 
stabilization follows the order: Mg2+>Ca2+>Mn2+>Ba2+>>Li+>Na+≈K+≈Cs+.32 
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1.4 Modified Nucleic Acids 
Modifications made on nearly every site of nucleosides have been investigated 
by scientists for various purposes. Most importantly, the modified nucleic acids can 
serve as pharmaceutical drugs or be used as tools to understand more about the 
biological rule of nucleic acids. Modifications also alter the stability and conformation 
of the double helix. Changes can be made to the nucleobase, pentose sugar, the 
phosphate backbone or any combination of above. 
Base modification has the potential to enhance the stability of nucleic acids by 
altering hydrogen bonding as well as base stacking. 2-amino-deoxyadenosine 
(compound 1.1) was synthesized in 1972.33 The extra amino group installed provides 
an extra hydrogen bonding site, and the modified nucleoside has the potential to form 
three hydrogen bonds. Results have shown that the modification results in a free 
energy gain from base pairing, and has better recognition for complimentary strand. 
 
Figure 1.14 Nucleosides with modified base.  
For compound 1.2, the adenine nucleobase is altered by an additional phenyl ring, 
which results in an expanded π conjugated system. This large aromatic system 
enhances the base stacking interaction with adjacent base pairs and increases 
stability.34 Also, non-expanded systems lacking the hydrogen bonding sites 
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(Compound 1.3) can be incorporated into nucleic acids which prove that base stacking 
is the primary driving force for helix formation.35,36 
Sugar modification can be achieved by adding additional groups, replacing 
native atoms with non-traditional heteroatoms, or changing the size of the ring. In 
locked nucleic acids (LNA, compound 1.4), O2’ and C4’ is linked by a methylene 
group. This extra linkage locks the sugar to C3’-endo conformation, which mimics 
A-form DNA and RNA. Studies have shown that nucleic acids with incorporated 
LNA nucleotides tend to form an A-form helix, and have enhanced affinity for 
complimentary DNA or RNA strands, resulting in significant increases in melting 
temperatures.37-39  
 
Figure 1.15 Nucleosides with modified sugar.  
Studies have shown that an electronegative substituent at C2’ position makes the 
C3’-endo conformation more favorable. 2’-Floro-deoxyuridine (Compound 1.5) has 
been shown to resist the excision repair activity of human G/T glycosylase and results 
in a tight-binding DNA-glycosylase complex.40 The atoms on the sugar ring itself can 
be altered. The ring oxygen can be substituted with sulfur to give 4’-thiofuranose 
(Compound 1.6). Oligonucleotides containing this modified nucleoside have been 
used to probe protein-DNA interactions.41,42 Lastly, the ring size can also be 
manipulated. Hexose sugars (Compound 1.7) can inhibit enzyme machinery. However, 
  17 
 
they are not stable in a DNA duplex, which helps to understand the evolution of 
pentose sugars in native oligonucleotides.43,44 
Phosphate modification is usually achieved by replacing the phosphate oxygen 
with other atoms or groups,45,46 substitution with sulfur and methyl group are the most 
studied. Methylphosphonate was first developed by Miller in 1979 (Figure 1.16 a).47 
Studies have shown that the compound was able to be incorporated into nucleic acids. 
With the phosphorothiolate linkage (Figure 1.16 b), a distinct chiral center is created. 
This facilitated the study of stereo specific interactions along the nucleic acid 
backbone.45 
 
Figure 1.16 Backbone modifications.  
a. Methylphosphonate, b. Phosphorothionate, c. PNA. 
Backbone modifications also include the creation of a completely novel 
backbone. The well-studied example is peptide nucleic acids (PNA, Figure 1.16 c). 
The backbone of PNA is made up of repeating N-(2-aminoethyl) glycine units linked 
by a peptide bond. And the bases are attached by a carbonyl and methylene group.48,49 
The number of atoms per repeating unit is identical to that of native DNA and RNA. 
Complementary single strands of PNA are known to form duplexes with themselves 
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and with complimentary DNA or RNA. The lack of a phosphate groups makes PNA 
electrically neutral, eliminating the charge repulsion and making it useful in triplex 
research.50,51 
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Chapter 2  
 
Towards the synthesis of 2’-deoxy-6,3’-propanouridine and 
2’-deoxy-6,3’-butanouridine 
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2.1 Introduction to Rigidified and Cyclo Nucleosides  
The formation and dissociation process of a nucleic acid is important in many 
biological functions such as DNA replication and translation. Many efforts have been 
made by scientists to develop modified nucleosides for studying and altering duplex 
stability and structure. One successful class of modifications is generally termed 
rigidified nucleosides which refer to modifications that reduce the overall flexibility 
of the nucleoside. By restricting some free bond rotations and angles, we may be able 
to make the formation of nucleic acid duplex more favorable using these rigidified 
monomers. 
Locked nucleic acid (LNA) is one famous example of rigid nucleoside. The U 
and C monomers were first synthesized by Imanishi group in 1997,1 and then 
individually synthesized by Wengel group in 1998 along with A, T, G, and 
5-methylcytosine.2 The ribose sugar of LNA is modified with an extra methylene 
group connecting the 2’ oxygen and 4’ carbon. The bridge locks the sugar pucker to 
3’-endo conformation which makes LNA containing duplexes tend to form A-form 
helical structures.  
 
Figure 2.1 LNA monomer structure, and illustration of locked 3’-endo conformation 
LNA can bind to itself, and can also be mixed with DNA and RNA to form stable 
duplex. The locked conformation enhances base stacking and backbone 
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pre-organization. The fixed 3’-endo conformation reduces the entropic cost caused by 
sugar flipping between 2’-endo and 3’-endo conformation. Thus, duplexes with 
incorporation of LNAs are more stable, shown by the increase in melting temperature 
(Tm).3,4 LNAs also have increased target specificity, and are resistance to exo- and 
endonucleases. These properties made LNA a useful tool in molecular biology 
techniques based on oligonucleotides, such as DNA microarray, and RNAi. 
Cyclonucleosides are another class of rigidified nucleosides. An extra bridge is 
installed connecting either the C6 of pyrimidines or the C8 of purines to the 
(deoxy)ribose sugar moiety. This modification fixes the base into an 
anti-conformation and prevents it’s rotation around the glycosidic bond. 
 
Figure 2.2 Examples of previously studied cyclo-2’-deoxynucleosides.5,6 
By limiting the rotation of the base, the entropic cost during duplex formation is 
lowered. However in order to form a more stable duplex, many other effects need to 
be taking into account. First, with the addition of an extra linkage, the position of the 
nucleobase is often times changed, usually being pulled back from the helix center, 
which forbids the formation of efficient hydrogen bonds. Second, the χ angle, which 
relates the position of the base to C1’-O5’ bond (Figure 1.5), may also be changed. 
This bond angle is an important factor dictating whether the helix adopts an A form or 
B form helical conformation. Lastly, for compound 2.1 through 2.4, the C4’-C5’ bond 
  23 
 
angle (γ) may potentially become problematic. In native nucleosides, the projection of 
O5’ should be on the sugar plane, while in these cyclonucleosides, the extra linkage 
forces O5’ to point out of the sugar plane. 
These cyclonucleosides have been thoroughly studied by our group and many 
others.6-14 The factors discussed above play an important role in the stability and 
conformation of the modified double helix. The synthesis and biological properties of 
some cyclonucleosides will be discussed in the following sections. 
 
2.2 Previous Cyclonucleosides Studies  
Initial studies in our group focued on the synthesis and evaluation of 
6,5’-cyclo-2’-deoxyuridine (Compound 2.1) and 8,5’-cyclo-2’-deoxyadenosine 
(Compound 2.2), which resemble the oxidative damage product of native 
nucleosides.15,16 These cross-linked modifications have important genetic implications; 
they are involved, for example, in processes such as gene expression inhibition and 
transcriptional mutagenesis.17,18 For synthesis involving 2’-deoxyuridine, the uracil 
nucleobase (lacking the 5-methyl group) was utilized instead of the naturally 
occurring thymidine nucleobase because of synthetic limitations. Studies have shown 
that 2’-deoxyuridine is a sufficient mimic for thymidine.19-21 
The synthesis of 6,5’-cyclo-2’-deoxyuridine (Compound 2.1) was accomplished 
by Dr. Hongchuan Yu, and the syntheisis of 8,5’-cyclo-2’-deoxyadenosine 
(Compound 2.2) has been successfully carried out by Dr. Han Yueh in our group.6 The 
two cyclonucleosides were then incorporated into oligonucleotides. Sequences of 
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12-mer and 14-mer oligonucleotides containing d(AAAA)/d(TTTT) in the center 
were designed, shown in figure 2.3. Cyclonucleosides were successfully incorporated 
into these sequences and were shown to be able to form duplexes with complimentary 
DNA.  
 
Figure 2.3 Melting temperature studies of DNA containing cylconucleosides.6 
However, thermal melting (Tm) studies indicated that duplexes containing 
cyclonucleosides possess much lower melting temperatures than the corresponding 
native duplexes, suggesting that the duplexes were destabilized by the incorporation 
of these cyclonucleosides. Circular dichroism (CD) studies of these duplexes showed 
that sequences containing cyclonucleosides retain a B-form duplex structure. 
The destabilization of the duplex can be explained by the structural change of 
nucleoside. Shown in figure 2.4 is the crystal structure of the two cyclonucleosides 
comparing with native dA and dU in B-DNA. First, the extra bond between sugar and 
base pulled the nucleobase back towards the sugar-phosphate backbone, disturbing 
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the formation of efficient hydrogen bonding and base stacking. Second, the torsion 
angle is changed to resemble A-form DNA more than B-form. Lastly, the orientation 
of C4’-C5’ bond is forced to point away from the sugar ring, while it points towards 
the heterocyclic base in native strands. 
 
Figure 2.4 Crystal structure of 8,5’-cyclo-2’-deoxyadenosine and 
6,5’-cyclo-2’-deoxyuridine overlaid with 2’-dA and 2’-dU adopted from B-DNA.6 
Based on these structural analyses, two second generation of cyclonucleosides 
were designed and synthesized in our group. Their structures are shown in figure 2.5. 
The synthesis of 6.5’-cyclo-2’-deoxyuridine with a 6’ hydroxyl (Compound 2.3) was 
accomplished by Dr. Hongchuan Yu. The introduction of a 6’ hydroxyl pushes the 
nucleobase back towards the helical center for the formation of more efficient 
hydrogen bonds. Also, the C5’-C6’ bond is now free to rotate, and can adopt a 
conformation that resembles native DNA. 
 
Figure 2.5 Second generation of cyclo-2’-deoxyuridine. 
The synthesis starts from 2’-deoxyuridine, acetyl protecting groups were 
installed on both 3’ and 5’ hydroxide. A 5-chloro was installed in order to facilitate the 
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aromatic recovery after the cyclization. And then three protecting group reactions 
were performed before iodide substitution gave compound 2.9. After the free radical 
cyclization, 5-chloro was removed to regenerate the double bond in 2.12. An 
oxidation reaction was then performed and installed a carbonyl group on C5’, which 
is then transformed into 5’ epoxide 2.14. The epoxide is hydrolyzed, and two isomers 
of 6’hydroxide 2.15 were produced. 
 
 
Scheme 2.1 Synthesis of 6’-hydroxyl-6,5’-cyclo-2’-deoxyuridine, work with Dr. Yu 
Although DMTr group is usually used for 5’-OH protection during standard 
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oligonucleotide synthesis, the steric hindrance around 6’ hydroxide of our cyclized 
nucleoside forbid the installation of the large DMTr group.16 So we used a less bulky 
acid labile protection group, ethyl vinyl ether (EVE) instead. Surprisingly, after the 
installation of 5’ EVE group and deprotection of 3’ hydroxyl, only the R-diastereomer 
2.16 was found, suggesting that the S-diastereomer was decomposed during the 
synthesis. 
Our effort to incorporate phosphoramidite 2.17 into oligonucleotides was 
unsuccessful, because the 5’-H was very vulnerable to the treatment with base during 
deprotection. Even when we used ultramild synthesis and deprotection procedures, the 
integrity of the sequence was not maintained. Our proposed mechanism of cleavage is 
shown in figure 2.6. The same 5’-H vulnerability in a similar structure have been 
shown in a previous study.22 
 
Figure 2.6 Dissociation mechanism of modified oligonucleotide under basic deprotection.23 
Meanwhile, the ring expanded 6,6’-cyclo-2’-deoxyuridine (Compound 2.4) was 
synthesized by Dr Chris Theile.24 The crystal structure of this cyclonucleoside 
overlaid well with thymidine cut from a B-form double helix as illustrated in figure 
2.7. The additional methylene group pushes the nucleobase back towards the helical 
center which may allow for the formation of more efficient hydrogen bond. Also, a 
longer linker may allow the χ angle to be somewhat flexible, potentially making base 
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stacking more efficient. However, the thermal temperature (Tm) study data was 
inconclusive. Most of the modified strands were not able to form duplex. We 
concluded that significant structural difference may cause backbone disturbance, 
inhibiting this ring-expanded cyclonucleoside from forming a stable duplex. 
 
Figure 2.7 Crystal structure of 6,6’-(S)-cyclo-2’-deoxyuridine overlaid with dT adopted 
from B-DNA.24 
In 1980s, Ueda et al. published another class of cyclonucleosides (Compound 
2.18, 2.19), in which the C6 of the pyrimidine nucleobase or the C8 of purine 
nucleobase was connected to the C3’ of the sugar ring.5,25 In these types of 
cyclonucleosides, the sugar puckering is fixed into the C3’-endo conformation, and 
the torsion angle is constrained.26 Researchers claimed this type of modification to be 
a good mimic for B-form nucleosides in DNA, which is however arguable because the 
fixed C3’-endo conformation is typical observed in A-form double helices. 
Studies of 6,3’-methanodeoxyuridine, compound 2.19, incorporated into DNA 
indicated that the thermal stabilities were decreased with the incorporation of 
modified nucleosides, although the modified strands showed resistance to nuclease.  
The nucleobase of 6,3’-methanodeoxyuridine has been significantly twisted and 
pulled back towards the sugar-phosphate backbone, preventing the formation of native 
hydrogen bonds and disturbing base stacking, thus, destabilizing the DNA duplex. 
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Figure 2.8 Compound 2.5 and 2.18 are 6,3’-carbon bridged nucleosides, Ueda et al. 
Compound 2.19 is 2’-O-methyl-6,3’-ethano-cyclouridine, Freier et al. Compound 2.20 is 
6,3’-propanodeoxyuridine. Compound 2.21 is 6,3’-butanodeoxyuridine. 
In an attempt to overcome this distorted conformation in the nucleoside, Freier et 
al. investigated 6,3’-ethanonucleoside, compound 2.20, in which the length of the 
carbon bridge is increased by one methylene group.27 This modification indeed 
increased the thermal stability slightly, but the modified strands still possessed 
decreased Tm values compared to the native strands. This result indicated that 
elongating the carbon bridge helped position the nucleobase to fit the requirement of 
duplex formation. In other words, a longer linker gives the nucleoside some flexibility 
so that the conformation of the nucleoside can be adjusted to fit into the duplex. 
Based on these previous studies, we concluded that a modified nucleoside with 
too much structural constraint could disturb the formation of a stable duplex. However, 
experiments have shown that too much conformational flexibility would induce 
drastic drops in binding affinity as well. Therefore, we wanted to design a structure 
which maintains a certain degree of conformational constraint to pre-organize the 
nucleoside into a conformation similar to what is found in duplex. Our plan was to 
further elongate the carbon bridge between C3’-C6 by investigating both 
6,3’-propanodeoxyuridine (Compound 2.20) and 6,3’-butanodeoxyuridine 
(Compound 2.21). 
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2.3 Crystal Modeling Comparison with Native 2’-deoxythymidine 
 
Figure 2.9 Molecule model comparison of rigid nucleosides with native A form dT 
Overlayed atoms: C1’, C2’, C4’.   a. 6,3’-methanodeoxyuridine (green)                     
b. 6,3’-propanodeoxyuridine (yellow)  c. 6,3’-butanodeoxyuridine (pink) 
Our current goal is the synthesis and evaluation of bridge elongated 
6,3’-cyclodeoxyuridines. Since the sugar puckering will likely be locked to C3’-endo 
conformation, the cyclo dU molecular models are compared to nucleotides excised 
from an A-form duplex structure. Modeling studies show that with a three carbon 
bridge, 6,3’-propano dU places the nucleobase almost in the same position as it is in a 
native A form duplex, with only a minor twist. 6,3’-butano dU is postulated to push 
the nucleobase away from the sugar, but the base is almost coplanar to that of the 
native one. With the flexibility of a long carbon bridge, the conformation of the 
nucleoside can be adjusted to fit within a duplex. We expect that the incorporation of 
these cyclonucleosides into a nucleic acid duplex will result in the formation of a 
more stable structure. 
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2.4 Synthetic Approach to 2’-deoxy-6,3’-butanouridine 
The syntheses of 2’-deoxy-6,3’-butanouridine and 2’-deoxy-6,3’-propanouridine 
were carried out simultaneously. The two cylconucleosides were designed to have a 
moderate flexibility and a restricted glycosidic preorganization, which should lead to 
high affinity of the incorporated oligonucleotide for its complement in DNA strands. 
The synthetic progress of 2’-deoxy-6,3’-butanouridine will be discussed in this 
section. 
Considering that the glycosidic bond is vulnerable under basic reaction 
conditions required for the cross-coupling reaction, the carbon chain and the 
nucleobase needs to be installed on C3’ before the glycosylation reaction. 
 
Scheme 2.2 Attempted synthesis of 2’-deoxy-6,3’-butanouridine 
The synthesis began with isopropylidene protection of D-xylose using copper (II) 
sulfate and acetone. The resulting product was then partially hydrolyzed under acidic 
condition to yield 1’,2’-isopropylidene protected sugar 2.23. The 5’-hydroxyl group 
was then selectively protected using TBSCl in pyrimidine followed by the oxidation 
of 3’-hydroxyl group using chromium trioxide in pyrimidine to generate compound 
2.25. Then our strategy was to synthesize a hetereocyclic base with the carbon bridge, 
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reactant 2.27, so we can couple it to the C3’ position. 
 
Scheme 2.3 Attempted synthesis of reactant 2.25 
Thymidine base was chlorinated using phosphoryl chloride in toluene, followed 
by methylation at C2 and C4 position with sodium methoxide in methanol. The four 
carbon bridge was installed by LDA catalyzed reaction of compound 2.30 and ethyl 
3-bromopropanoate. The resulting compound 2.31 was then reduced by LAH to yield 
compound 2.32. The terminal hydroxyl group is replaced by sulfonyl group in DCM, 
and then substituted by iodide in acetone, in order to get ready for the coupling 
reaction with the sugar moiety. Unfortunately, compound 2.34 was extremely unstable; 
the nucleophilic N1 would attack the terminal carbon, resulting in the formation of a 
six member ring. After the reaction, only compound 2.35 were found as a product. 
Since the synthesis of nucleobase moiety with the carbon bridge was 
unsuccessful due to the presence of unstable intermediates, our new strategy was to 
couple the carbon linker to the sugar moiety first, then attach the nucleobase to the 
other end of the linker. Therefore, a three carbon linker was added onto the C3’ of 
compound 2.25 through Grignard reaction with 3-chloropropanol. Then carbon 
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tetrabromide and triphenylphosphine were used to convert the hydroxyl to a bromo 
group producing compound 2.37. A cross-coupling reaction between compound 2.37 
and 2.30 catalyzed by LDA successfully generated compound 2.38. 
 
Scheme 2.4 Towards the synthesis of 2’-deoxy-6,3’-butanouridine 
The 5’ silyl group was changed to benzoyl protecting group, yielding 2.39, in 
order to withstand the following acidic reaction condition. Isopropylidene was 
removed under acidic conditions and acetyl protecting groups were installed, creating 
compound 2.40 for the glycosylation reaction. However, the glycosylation reaction 
catalyzed by SnCl4 was unsuccessful and the second connection between sugar and 
base was not achieved. Most of the starting material was recovered. 
We postulate that the flexibility of the long carbon chain brings the nucleobase to 
random place, so although C1’ is activated, N1 is far away from where it could 
perform the nucleophilic attack. Futhermore, even though the nucleobase is 
potentially positioned for an intramolecular reaction with the sugar, the large ring 
strain would most likely preclude the product from being stable. 
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2.5 Synthetic Approach to 2’-deoxy-6,3’-propanouridine 
We then investigated 2’-deoxy-6,3’-propanouridine, hoping that with a linker 
that is shortened by one carbon, N1 could perform the nucleophilic attack on C1’. The 
synthetic pathway we chose was similar to that of 2’-deoxy-6,3’-butanouridine. An 
(Ethylcarbonyl)-methyl group was installed on C3’ through zinc catalyzed reaction. 
Followed the reduction by LAH and bromination by carbontetrabromide, compound 
2.43 was produced. A cross-coupling reaction between compound 2.43 and 2.30 
catalyzed by LDA successfully generated compound 2.44. The 5’ silyl group was 
changed to benzoyl protecting group, yielding 2.45. Isopropylidene was removed 
under acidic conditions and acetyl protecting groups were installed, creating 
compound 2.40. Unfortunately, the glycosylation encountered the same problem. We 
propose that, again, the ring strain was too great to allow the second linkage between 
the sugar and nucleobase. 
 
Scheme 2.5 Towards the synthesis of 2’-deoxy-6,3’-propanouridine 
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2.6 Results and Discussion 
The syntheses of two novel cyclodeoxyuridines were designed. Both of these 
nucleosides could potentially lock the sugar puckering into the C3’-endo 
conformation, and fix the nucleobase into and anti-conformation. Moreover, the 
nucleobase in these modified nucleosides is positioned to mimic their native 
conformation in an A-form duplex, allowing efficient hydrogen bonding and base 
stacking and potentially more stable duplexes. Unfortunately, the synthesis of these 
two compounds was unsuccessful because of the strain associated with the formation 
of 8- or 9-membered ring structures. Powerful glycosylation conditions need to be 
discovered in the future to facilitate the ring formation in our synthesis. 
 
2.7 Experimental procedures 
Chemicals were purchased from Sigma-Aldrich, Acros, Oakwood, Lancaster, 
Chem-Impex International, Fisher, Chem Genes and Molekula. Anhydrous 
tetrahydrofuran (THF), diethyl ether (Et2O), N,N-dimethylformamide (DMF), 
pyridine (pyr), acetonitrile (MeCN), and dichloromethane (DCM) were HPLC grade 
and further purified by passing through activated alumina columns. Anhydrous 
ethanol was purchased from Sigma-Aldrich and used directly. Anhydrous methanol 
was distilled over magnesium and iodide prior to use. Silica gel (60 Å, particle size 
40-63 μm) was used for flash chromatography and TLCs with F-254 Indicator were 
visualized by 260nm UV light and stained by 10% sulfuric acid. NMR spectra were 
taken by Varian VNMRS400, VNMRS500, or INOVA 500 instruments and calibrated 
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using residual undeuterated solvent (CDCl3: δ H = 7.24 ppm, δ C = 77.23 ppm, 
DMSO-d6: δ H = 2.50 ppm, δ C = 39.51 ppm, Methanol-d4: δ H=3.31 ppm, δ C = 
49.15 ppm). Abbreviations of multiplicities were designated as follow: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet. High-resolution mass spectra (HRMS) 
were recorded on a Waters LCT or JEOL AccuTOF 201 mass spectrometer using ESI 
(electrospray ionization) or DART (direct analysis in real time). 
Compound 2.23  
D-xylose (5.0 g, 33.3 mmol) and anhydrous copper sulfate (7.0 g, 43.9 mmol) 
were dissolved in anhydrous acetone (100 mL). After cooled to 0℃, concentrated 
sulfuric acid was slowly added (0.5 mL, 10.1 mmol). Then the reaction flask was 
warmed to room temperature, and stirred for 24 hours. 0.1M HCl (11.0 mL) was 
added into the reaction mixture, and then the reaction temperature was raised to 40℃ 
and stirred for 2 hours. After cooling to room temperature, the reaction mixture was 
neutralized with saturated sodium bicarbonate. Insoluble copper sulfate was filtered 
off and washed with methanol. Filtrate was concentrated under reduced pressure and 
purified by flash chromatography (10% MeOH, 90% DCM) to yield compound 2.23 
as yellow oil (18.6 g, 56%). 1H NMR (500 MHz, CDCl3) δ 5.97 (d, J=3.5 Hz, 1H), 
4.51 (d, J = 3.5 Hz, 1H), 4.32 (t, J =3 Hz, 1H), 4.04 - 4.17 (m, 2H), 3.76 (d, J = 3.5 
Hz, 1H), 1.47 (s, 3H), 1.31 (s, 3H); 13C NMR (100 MHz, CDCl3), δ 112.0, 105.1, 
85.9, 78.7, 77.4, 61.6, 27.0, 26.4. HRMS (DART) Calcd. Mass for C8H15O5 191.0920, 
found: 191.0934. 
  37 
 
 
Compound 2.24  
A mixture of compound 2.23 (7,4 g, 38.9 mmol) and TBDMSCl was dissolved in 
pyridine (80.0 mL) and stirred at room temperature for 4 hours. Solvent was removed 
under reduced pressure, and the residue was taken up by ethyl acetate (250 mL), 
washed with water (2×150 mL) and brine (200 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered and then concentrated under reduced pressure and purified 
by flash chromatography (10% EtOAc, 90% Hexanes) to yield compound 2.24 (11.2 g, 
95%) as yellow oil. 1H NMR (500 MHz, CDCl3) δ 5.94 (d, J=4.0Hz, 1H), 4.48 (d, J 
= 3.2 Hz, 1H), 4.35 (d, J=2.4 Hz, 1H), 4.30 (m, 1H), 4.11 (s, 1H), 4.09-4.12 (m, 2H), 
1.46 (s, 3H), 1.30 (s, 3H), 0.87 (s, 9H), 0.092(s, 3H), 0.087(s, 3H); 13C NMR (100 
MHz, CDCl3), δ 111.7, 105.2, 85.8, 78.3, 77.4, 62.6, 27.1, 26.4, 25.9, 18.4, -5.29, 
-5.42. HRMS (DART) Calcd. Mass for C14H29O5Si 305.1784, found: 305.1793. 
 
Compound 2.25  
Compound 2.24 (6.2 g, 20.4mmol) was dissolved in DCM (20 mL), and was added 
into previously prepared DCM solution (100 mL) containing CrO3-Pyridine-Ac2O 
(5.88 g, 58.8 mmol: 10 mL: 2.0 mL). The mixture was stirred at room temperature for 
3 hours, and then added dropwise to ethyl acetate (500mL) while stirring. The 
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precipitate was filtered off and the filtrate was concentrated. The residue was purified 
by flash chromatography (5% EtOAc, 95% Hexanes) to yield white solid compound 
2.25 (4.5 g, 73%). 1H NMR (500 MHz, CDCl3) δ 6.12 (d, J=4.8 Hz, 1H), 4.36 (m, 
1H), 4.26 (d, J=4.4 Hz, 1H), 3.80-3.89 (m, 2H), 1.45 (s, 3H), 1.44 (s, 3H), 0.85 (s, 
9H), 0.05 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3), δ 211.3, 114.4, 104.0, 
82.0, 77.3, 64.2, 27.9, 27.4, 26.0, 18.4, -5.30, -5.49. HRMS (DART) Calcd. Mass for 
C14H27O5Si 303.1622, found: 303.1893. 
 
Compound 2.30  
Thymine (5 g, 39.6 mmol) and Phosphoryl chloride (18.1 mL, 198.2 mmol) were 
dissolved in dry toluene (100 mL), and TEA (10.1 mL, 79.3 mmol) was added. The 
reaction mixture was heated to reflux for 3 hours. After reaction, the flask was cooled 
to room temperature and filled with ice water (80 mL). The organic layer was 
separated, and the aqueous layer was extracted with toluene (2×100 mL). Then, the 
combined organic layer was dried over anhydrous sodium sulfate. After filtration, the 
organic layer was concentrated to yield yellowish oil. The crude was found pure 
enough to be carried on for the following reaction.  
The crude was dissolved in 120 mL methanol/ether (methanol/ ether 3:1). A 25% 
wt. NaOMe in methanol (22.7 mL, 4M) was slowly added into the reaction flask 
during 1 hour. The reaction was heated to reflux for 3 hours. After removing volatiles, 
the residue was diluted with DCM (100 mL) and water (10 mL), and then extracted 
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with DCM (3×50 mL). Organic layer was concentrated and applied to flash 
chromatography (10% EtOAc, 90% Hexanes) to yield compound 2.30 (3.85 g, 63%) 
as white powder. 1H NMR (500 MHz, CDCl3) δ 6.19 (s, 1H), 3.95 (s, 3H), 3.92 (s, 
3H), 2.33 (s, 3H); 13C NMR (125 MHz, CDCl3), δ 172.1, 169.3, 165.4, 100.3, 54.8, 
53.8, 24.0. HRMS (DART) Calcd. Mass for C7H11N2O2 155.0815, found: 155.0779. 
 
Compound 2.36  
A solution of 3-chloropropanol (2.49 mL, 29.8 mmol) in THF (10 mL) was 
cooled to -20℃. Tert-butyl magnesium chloride (29.8 mL. 1M in THF) was added 
dropwise. The reaction was kept stirring at -20℃ for 20 minutes before warmed to 
room temperature. Magnesium stripes (1.084 g, 44.6 mmol) were added to the 
reaction flask along with 2 drops of dibromomethane. The reaction was heated to 
reflux for 3 hours, and then cooled to room temperature. A solution of compound 2.25 
(3.0 g, 9.9 mmol) in THF (10 mL) was added slowly, and then reaction continues at 
room temperature for 2 hours. After cooled to 0℃, the reaction was quenched with 
saturated NH4Cl. Remaining magnesium was filtered off and washed with EtOAc. 
Aqueous layer was separated and extracted twice with EtOAc. Organic layers were 
combined, concentrated under reduced pressure, and applied to flash chromatography 
(10% EtOAc, 90% Hexanes) to yield compound 2.36 (3.13 g, 87%). 1H NMR (500 
MHz, CDCl3) δ 5.76 (d, J=4.0 Hz, 1H), 4.30 (d, J=4.0 Hz, 1H), 3.89 (dd, J=6.5 Hz, 
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J=4.0 Hz, 1H), 3.73-3.82 (m, 2H), 3.65-3.68 (m, 2H), 1.72-1.82 (m, 2H), 1.62-1.71 
(m, 2H), 1.57 (s, 3H), 1.35 (s, 3H), 0.88 (s, 9H), 0.06 (s, 6H). HRMS (DART) Calcd. 
Mass for C17H35O6Si 363.2197, found: 363.2549. 
 
Compound 2.37  
Compound 2.36 (3.95 g, 10.88 mmol) was dissolved in anhydrous DCM (20 mL) 
together with carbontetrabromide (4.33 g, 13.06 mmol). The reaction flask was cooled 
to 0℃. Then a solution of triphenylphosphine (3.43 g, 13.06 mmol) in DCM (15 mL) 
was added dropwise over 20 min. After addition, the reaction was kept stirring at 0℃ 
for 1 hour, then warmed to room temperature and continue stirred for 2 hours. The 
reaction was quenched with water, and then solvents were removed under reduced 
pressure. Residue was purified by flash chromatography (20% EtOAc, 80% Hexanes) 
to yield compound 2.37 as yellow oil (3.87 g, 84%). 1H NMR (500 MHz, CDCl3) δ 
5.77 (d, J=4.0 Hz, 1H), 4.26 (d, J=4.0 Hz, 1H), 3.89 (dd, J=6.0 Hz, J=4.3 Hz, 1H), 
3.75-3.82 (m, 2H), 3.36-3.51 (m, 2H), 1.70-2.13 (m, 4H), 1.57 (s, 3H), 1.34 (s, 3H), 
0.88 (s, 9H), 0.07 (s, 6H). HRMS (DART) Calcd. Mass for C17H34BrO5Si 425.1353, 
found: 425.1460. 
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Compound 2.38  
Compound 2.30 (886 mg, 5.75 mmol) was dissolved in THF (10 mL) and cooled 
to -78℃. LDA (3.7 mL, 1.4 M) was slowly added to reaction flask. The temperature 
was kept at -78℃ for 5 minutes then raised to -61℃, and reaction solution was 
stirred for 45 min. After reaction mixture was added with NaI (17 mg, 0.12 mmol), 
compound 2.37 (980 mg, 2.30 mmol) in THF (10 mL) was slowly added into the 
reaction flask at -61℃. Then the temperature was raised to -40℃, and the reaction 
mixture was stirred for 1.5 hours. The reaction was warmed to room temperature 
before quenched with saturated NH4Cl and concentrated under reduced pressure. 
Residue was taken up by DCM and washed with water twice. Organic layer was 
collected, dried over Na2SO4 and applied to flash chromatography (20%EtOAc, 80% 
Hexanes) to yield compound 2.38 (248 mg, 22%) as colorless oil. 1H NMR (500 
MHz, CDCl3) δ 6.19 (s, 1H), 5.66 (d, J=3.5 Hz, 1H), 4.13 (t, J=5.0 Hz, 1H), 4.09 (q, 
J=3.5 Hz, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.88-3.91 (m, 2H), 3.73-3.80 (m, 2H), 
2.08-2.15 (m, 2H), 1.92-1.98 (m, 2H), 1.58 (s, 3H), 1.48-1.54 (m, 2H), 1.32 (s, 3H), 
0.87 (s, 9H), 0.05 (s, 6H). HRMS (DART) Calcd. Mass for C24H43N2O7Si 499.2834, 
found: 499.2948. 
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Compound 2.39  
Compound 2.38 (248 mg, 0.50mmol) was dissolved in THF (2 mL) along with 
TBAF (0.5 mL, 1M). The mixture was stirred at room temperature for 10 minutes, 
solution turned orange color. Solvent was removed under reduced pressure and crude 
is used for next step.  
Crude was dissolved in pyridine (3 mL) and cooled to 0℃, and then benzoyl 
chloride (0.14 mL, 1.25 mmol) was added. The reaction was stirred at room 
temperature for 12 hours. Solvent was removed under reduced pressure and residue 
was co-evaporated with toluene three times. Then the residue was taken up by 
chloroform and washed subsequently with water, saturated NaHCO3, and brine 
solution. The organic layer was dried over Na2SO4 and filtered. Flash chromatography 
(30% EtOAc, 70% Hexanes) was applied to yield compound 2.39 (186 mg, 89%). 1H 
NMR (500 MHz, CDCl3) δ 8.05 (m, 2H), 7.54 (m, 1H), 7.41 (m, 2H), 6.18 (s, 1H), 
5.80 (d, J=4.0 Hz, 1H), 4.55 (dd, J=12.0 Hz, J=3.5 Hz, 1H), 4.37 (dd, J=12.0 Hz, 
J=8.5 Hz, 1H), 4.30 (d, J=4.0 Hz, 1H) 4.09 (m, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 2.60 (t, 
J=7.5 Hz, 2H), 1.60-1.77 (m, 4H), 1.58 (s, 3H), 1.39-1.49 (m, 2H), 1.36 (s, 3H). 
HRMS (DART) Calcd. Mass for C25H33N2O8 489.2231, found: 489.2362. 
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Compound 2.40  
Compound 2.39 (168 mg, 0.34 mmol) was added into TFA (2 mL) and stirred at 
room temperature for 1.5 hours. Solvent was removed under reduced pressure. 
Residue was co-distilled with isopropanol three times before dissolved in a solution of 
DCM-TEA (1.67 mL : 0.33 mL). And then acetic anhydride (64 μL, 0.68 mmol) was 
added. Reaction was further stirred at room temperature for 2 hours. Reaction mixture 
was then diluted with chloroform, and washed subsequently with water, saturated 
NaHCO3 and brine solution. Organic layer was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Flash chromatography (50% EtOAc and 50% 
Hexanes) was performed to yield compound 2.40 (54 mg, 29%). 1H NMR (500 MHz, 
CDCl3) δ 8.10 (m, 2H), 7.56 (m, 1H), 7.44 (m, 2H), 6.16 (s, 1H), 6.14 (d, J=3.0 Hz, 
1H), 5.32 (d, J=3.0 Hz, 1H), 4.63 (dd, J=11.5 Hz, J=3.0 Hz, 1H), 4.29-4.37 (m, 2H) 
3.95 (s, 3H), 3.93 (s, 3H), 2.60 (t, J=7.5 Hz, 2H), 2.15 (s, 3H), 1.94 (s, 3H), 1.70-1.79 
(m, 4H), 1.55 (m, 2H). HRMS (DART) Calcd. Mass for C26H33N2O10 533.2130, found: 
533.2232. 
 
Compound 2.42  
Compound 2.25 (2.084 g, 6.89 mmol) and fresh washed zinc powder (676 mg, 
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10.34 mmol) were suspended in THF (4 mL). A solution of ethyl bromoacetate (2.3 
mL, 20.67 mmol) in THF (8 mL) was slowly added into the reaction flask. After 
adding, temperature was raised to 45℃ and stirred for 1.5 hours. The reaction 
solution was cooled to room temperature and quenched with saturated NH4Cl. 
Volatiles were removed under reduced pressure, and the residue was taken up by 
DCM, washed with water and brine. Organic layer was then concentrated and purified 
by flash chromatography (10% EtOAc, 90% Hexanes) to yield colorless oil 
compound 2.42 (2.37g, 88%). 1H NMR (500 MHz, CDCl3) δ 5.77 (d, J=4.0 Hz, 1H), 
4.66 (d, J=4.0 Hz, 1H), 4.15 (q, J=7.0 Hz, 2H), 3.95 (t, J=5.0 Hz, 1H), 3.81 (qd, 
J=11.0 Hz J=4.0 Hz, 2H), 3.35 (s, 1H), 2.67 (d, J=15 Hz, 1H), 2.42 (d, J=15 Hz, 1H), 
1.57 (s, 3H), 1.35 (s, 3H), 1.26 (t, J=6.0 Hz, 3H) 0.87 (s, 9H), 0.06 (s, 6H). 13C NMR 
(100 MHz, CDCl3), δ 171.3, 113.0, 104.2, 82.8, 81.9, 78.0, 61.4, 61.2, 37.3, 26.9, 26.8, 
26.1, 18.5, 14.3, -5.14, -5.19. HRMS (DART) Calcd. Mass for C18H34NaO7Si 
413.1966, found: 413.1991. 
 
Compound 2.43  
Compound 2.42 (2.69 g, 6.89 mmol) was dissolved in THF (30 mL), and cooled 
to 0℃. A solution of LAH (523 mg, 13.78 mmol) in THF (8 mL) was added. The 
reaction was kept at 0℃ for 10 minutes and then warmed to room temperature and 
stirred for 1 hour. The excess of LiAlH4 was eliminated by adding THF/water (7: 3, 
80ml). The reaction mixture was filtrated through celite and concentrated. The 
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obtained residue was purified by flash chromatography (10% Acetone, 90% DCM) to 
yield colorless oil (1.82 g, 76%) and is carried on to next reaction.  
Crude was dissolved in anhydrous DCM (12 mL) and pyridine (0.6 mL, 3 eq). 
Carbontetrabromide (1.74 g, 5.24 mmol) was added and the reaction flask was cooled 
to 0℃. Then a solution of triphenylphosphine (1.37 g, 5.24 mmol) in DCM (6 mL) 
was added dropwise over 20 min. After addition, the reaction was kept stirring at 0℃ 
for 1 hour, then warmed to room temperature and stirred for 2 hours. The reaction was 
quenched with water, and then the solvents were removed by rotary evaporator. 
Residue was taken up by DCM, washed with water and brine, organic layer was 
concentrated and purified by flash chromatography (10% EtOAc, 90% DCM) to yield 
product compound 2.43 as yellow oil (1.77 g, 82%). 1H NMR (500 MHz, CDCl3) δ 
5.79 (d, J=4.0 Hz, 1H), 4.37 (d, J=4.5 Hz, 1H), 3.85 (t, J=5.0 Hz, 1H), 3.75-3.81 (m, 
2H), 3.43-3.59 (m, 2H), 2.68 (s, 1H), 2.24-2.29 (m, 1H), 1.92-1.98 (m, 1H), 1.56 (s, 
3H), 1.35 (s, 3H), 0.88 (s, 9H), 0.07 (s, 6H); 13C NMR (100 MHz, CDCl3), δ 113.1, 
104.1, 83.4, 81.0, 79.3, 61.3, 35.7, 27.1, 26.8, 26.7, 26.1, 18.5, -5.11, -5.21. HRMS 
(DART) Calcd. Mass for C16H32BrO5Si
 411.1197, found: 411.1215. 
 
Compound 2.44  
Compound 2.30 (800 mg, 5.19 mmol) was suspended in THF (5 mL) at -78 °C. 
LDA (4.0 mL, 1.4 M) was slowly added to reaction flask. Then the temperature was 
  46 
 
raised to -61 °C, and reaction solution was stirred for 45 min. After added with NaI 
(13 mg, 0.17 mmol), compound 2.43 (710 mg, 1.73 mmol) in THF (5 mL) was slowly 
added into the reaction flask at -61 °C. Then the temperature was raised to -40 °C, and 
the reaction mixture was stirred for 1.5 hours. Thereafter, the reaction was quenched 
with saturated NH4Cl and concentrated. Residue was applied to flash chromatography 
(20% EtOAc, 80% Hexanes) to yield compound 2.44 (252 mg, 30%) as colorless oil. 
1H NMR (500 MHz, CDCl3) δ 6.20 (s, 1H), 5.72 (d, J=4.0 Hz, 1H), 4.32 (d, J=4.0 
Hz, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 3.87 (m, 1H), 3.69-3.79 (m, 2H), 2.59-2.69 (m, 
2H), 1.76-1.94 (m, 2H), 1.58-1.62 (m, 1H), 1.56 (s, 3H), 1.37-1.44 (m, 1H), 1.33 (s, 
3H), 0.86 (s, 9H), 0.04 (s, 6H); 13C NMR (125 MHz, CDCl3), δ 172.4, 172.1, 165.5, 
112.6, 104.1, 99.9, 83.7, 81.2, 78.9, 61.6, 54.7, 53.8, 37.7, 30.7, 26.7, 26.0, 22.0, 18.4, 
-5.15, -5.31. HRMS (DART) Calcd. Mass for C23H41N2O7Si 485.2683, found: 
485.2798. 
 
Compound 2.45  
Compound 2.44 (221 mg, 0.46 mmol) was dissolved in THF (2 mL) along with 
TBAF (0.46 mL, 1M). The mixture was stirred at room temperature for 10 minutes, 
solution turned orange color. Solvent was removed under reduced pressure and crude 
is used for next step.  
Crude was dissolved in pyridine (3 mL) and cooled to 0℃, and then benzoyl 
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chloride (0.11 mL, 0.92 mmol) was added. The reaction was stirred at room 
temperature for 12 hours. Solvent was removed under reduced pressure and residue 
was co-evaporated with toluene three times. Then the residue was taken up by 
chloroform and washed subsequently with water, saturated NaHCO3, and brine 
solution. The organic layer was dried over Na2SO4 and filtered. Flash chromatography 
(30% EtOAc, 70% Hexanes) was applied to yield compound 2.45 (161 mg, 74%). 1H 
NMR (500 MHz, CDCl3) δ 8.03 (m, 2H), 7.54 (m, 1H), 7.41 (m, 2H), 6.22 (s, 1H), 
5.78 (d, J=4.0 Hz, 1H), 4.53 (dd, J=14.5 Hz, J=3.0 Hz, 1H), 4.33-4.40 (m, 2H), 4.11 
(m, 1H), 3.98 (s, 3H), 3.95 (s, 3H), 2.68 (m, 2H), 1.84-1.99 (m, 2H), 1.68 (m, 2H), 
1.57 (s, 3H), 1.35 (s, 3H). HRMS (DART) Calcd. Mass for C24H31N2O8 475.2075, 
found: 475.2166. 
 
Compound 2.46  
Compound 2.45 (150 mg, 0.32 mmol) was added into TFA/water (1.8 mL : 0.2 
mL) and stirred at room temperature for 1.5 hours. Solvent was removed under 
reduced pressure. Residue was co-distilled with isopropanol three times before 
dissolved in a solution of DCM-TEA (2.0 mL : 0.4 mL). And then acetic anhydride 
(120 μL, 1.26 mmol) was added. Reaction was further stirred at room temperature for 
2 hours. Reaction mixture was then diluted with chloroform, and washed 
subsequently with water, saturated NaHCO3 and brine solution. Organic layer was 
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dried over Na2SO4, filtered and concentrated under reduced pressure. Flash 
chromatography (50% EtOAc and 50% Hexanes) was performed to yield compound 
2.46 (49 mg, 30%). 1H NMR (500 MHz, CDCl3) δ 8.06 (m, 2H), 7.55 (m, 1H), 7.43 
(m, 2H), 6.21 (s, 1H), 6.15 (d, J=2.4 Hz, 1H), 5.32 (d, J=2.4 Hz, 1H), 4.58 (dd, 
J=12.0 Hz, J=2.0 Hz, 1H), 4.38-4.40 (m, 1H), 4.28-4.32 (m, 1H) 3.99 (s, 3H), 3.96 (s, 
3H), 2.76 (m, 2H), 2.17 (s, 3H), 1.94 (s, 3H), 1.85 (m, 2H), 1.76 (m, 2H). HRMS 
(DART) Calcd. Mass for C25H31N2O10 519.1973, found: 519.2321. 
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2.8 1H and 13C NMR Spectra 
Compound 2.23 1HNMR (500 MHz, CDCl3) 
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Compound 2.23 13C NMR (100 MHz, CDCl3) 
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Compound 2.24 1H NMR (500 MHz, CDCl3) 
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Compound 2.24 13C NMR (100 MHz, CDCl3) 
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Compound 2.25 1H NMR (500 MHz, CDCl3) 
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Compound 2.25 13C NMR (100 MHz, CDCl3) 
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Compound 2.30 1H NMR (500 MHz, CDCl3) 
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Compound 2.30 13C NMR (100 MHz, CDCl3) 
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Compound 2.36 1H NMR (500 MHz, CDCl3) 
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Compound 2.37 1H NMR (500 MHz, CDCl3) 
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Compound 2.38 1H NMR (500 MHz, CDCl3) 
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Compound 2.39 1H NMR (500 MHz, CDCl3) 
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Compound 2.40 1H NMR (500 MHz, CDCl3) 
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Compound 2.42 1H NMR (500 MHz, CDCl3) 
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Compound 2.42 13C NMR (100 MHz, CDCl3) 
 
  64 
 
Compound 2.43 1H NMR (500 MHz, CDCl3) 
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Compound 2.43 13C NMR (100 MHz, CDCl3) 
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Compound 2.44 1H NMR (500 MHz, CDCl3) 
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Compound 2.44 13C NMR (100 MHz, CDCl3) 
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Compound 2.45 1H NMR (500 MHz, CDCl3) 
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Compound 2.46 1H NMR (500 MHz, CDCl3) 
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Chapter 3  
 
Synthesis of 3’ and 5’ Backbone Extended Nucleosides 
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3.1 Introduction to Backbone Extended Nucleosides 
Nucleic acids have important biological functions in all forms of life. Over the 
years, scientists have been making different modifications on nucleic acids in order to 
alter its biological properties. Modifications have been made on the heterocyclic bases, 
the (deoxy)ribose sugar moiety, and the phosphate backbone. In this chapter, only the 
backbone modifications will be discussed. 
PNAs (peptide nucleic acids) are probably the most famous backbone modified 
nucleic acids, first discovered by Peter E. Nielsen in 1991.1 Unlike DNA or RNA with 
a sugar-phosphate backbone, PNA is composed of modified glycine units linked by 
peptide bonds. The purine and pyrimidine bases are linked to the backbone by a 
carbonyl and a methylene group as shown in figure 3.1. These differences in the 
backbone structure give PNA properties distinct from DNA. The most important 
difference is that, without the negatively charged phosphate group, PNAs are neutral 
macromolecules. With less electrostatic repulsion, the binding between PNA/DNA is 
stronger compared to the binding of DNA/DNA. Meanwhile, studies have also shown 
that PNA binds with DNA or RNA with high specificity,2 which makes PNA an ideal 
tool in diagnostic assays and antisense therapeutics. Short PNA oligomers are enough 
to fulfill the requirement in these roles, which usually requires much longer 
oligonucleotide probes.3 
Morpholinos are another family of synthetic nucleic acid analogues. They bind 
with DNA or RNA via standard Watson-Crick base-pairing rules. The main structural 
difference is that instead of linking to sugar rings, the bases are bound to morpholine 
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rings, which are further linked together by phosphorodiamidate groups instead of 
phosphate groups. Morpholinos are well studied for their antisense therapeutic 
applications. IThey have the capability to bind to target mRNA and knock down gene 
expression, when one would like to know the function of a particular protein. In 
another application, morpholinos bind with pre-mRNA and modify splicing, 
commonly excluding exons from the mature mRNA.4 
 
Figure 3.1 Various native and backbone modified nucleic acids 
These nucleic acids with backbone modifications have shown their importance in 
biological applications and in the study of nucleic acid structure and stability.5-8 
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Similar to those discussed above, threofuranose nucleic acid (TNA) and glycol 
nucleic acid (GNA) also belong to backbone modified nucleic acids which previously 
have been carefully studied in our lab.9-14 In TNA, nucleosides are linked by 
phosphate groups from 3’ to 2’ positions. TNA binds DNA to form duplexes and can 
be accepted by DNA polymerase enzymes. GNA has a more simplified structure that 
lacks the pentose sugar ring. Studies have also shown that GNA can also be accepted 
by DNA polymerase enzymes to a certain extent.6 
Comparing the structure of TNA or GNA to native DNA and RNA, we find that 
TNA and GNA both feature a shorter backbone of four atoms from O2’ to O3’, while 
DNA and RNA have a 3’ to 5’ linkage of 5 atoms. We were, however, interested in 
making a nucleic acid with an extended backbone. The following sections will 
address the ongoing research on 5’ extended nucleosides, which feature an additional 
methylene group linked to the C5’ (Compound 3.3), On the other hand, we were also 
interested in 3’ extended nucleosides, which contain an additional methylene group 
linked to the C3’ (Compound 3.4). 
 
Figure 3.2 Comparison of backbone length between native and various modified dT 
Compound 3.1--native dT. Compound 3.2--thymidine in TNA.  
Compound 3.3--5’ extended dT. Compound 3.4--3’ extended dT.  
The motivation of this study is to see how an extended backbone will affect the 
stability and conformation of an oligonucleotide helix. Naturally, DNA and RNA 
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adopt different conformations under different conditions such as temperature, pH, and 
salt concentration. Different conformations give distinct properties that contribute to 
the function of organelles. With an extended backbone, we anticipate that a different 
type of helix could form.  
Initial work was done by Dr. Christopher Theile, who successfully synthesized 5’ 
extended dT (compound 3.3). In the effort of incorporating this modified dT* into 
oligonucleotides, we found that the strand with dT* become elongated while the 
complimentary strand containing dA would remain the same length. This difference in 
length may result in a destabilized duplex, and therefore triggers our thought to 
synthesize 5’ extended dA as well so that we can incorporate dT*---dA* base pairs 
into oligonucleotides. 
Yet, another problem exists with the incorporation of 5’ extended base pairs. At 
the junction of native and modified nucleosides, the spacing will be distorted. Because 
the strands are anti-parallel to each other, there will be a “5’-overhang” at each 
junction of native and extended nucleotides (Figure 3.3). This problem may be solved 
by pairing 3’ extended nucleotides on the complimentary strand. 
 
Figure 3.3 Duplex diagrams showing native nucleotides in black, 5’ extended in red, and 3’ 
extended in blue. 
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Figure 3.4 Base pair of 5’ extended dA and 3’ extended dT 
Current efforts have been set on the synthesis of both 5’ extended dA and 3’ 
extended dT. We are curious to incorporate these dA*-dT* base pairs into 
oligonucleotides to study the change of stability and conformation. Also, a strand with 
only the extended nucleotides will be made, and the formation of a new type of helix 
is anticipated. 
 
3.2 Work Towards the Synthesis of 5’ Extended 2’-deoxyadenosine 
Since Dr. Chris Theile in our group has successfully synthesized 5’ extended 
2’-deoxythymidine based on the work by Kofoed et al15, our first thought was to 
follow a similar synthetic route with adenosine as the nucleobase. As shown in 
scheme 3.1, the synthesis starts with four protecting group reactions. First, the amine 
group on adenosine is protected by benzoyl group through a transient protection 
procedure.16 Then a DMTr group is installed on the 5’-hydroxide, so that the 
3’-hydroxide can be selectively protected by TIPS group in THF. The 5’ DMTr group 
is then removed under acidic condition to form compound 3.6. 
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Scheme 3.1 Attempted hydroboration with adenosine, work by Eric Hardter 
Dess-Martin periodinane was then used to oxidize the 5’ hydroxide to provide 5’ 
aldehyde 3.7. Then a Wittig reaction gave the terminal olefin 3.8. Unfortunately, the 
hydroboration reaction with 9-BBN did not work on this intermediate. Using BH3 
instead of 9-BBN also failed to produce the desired product. Our hypothesis is that the 
boron complex reacted with the amine group on adenosine, instead of the terminal 
olefin. 
We then decided to use 2’-deoxyinosine as the starting material for our synthesis 
of 5’-extended dA. The reaction starts with converting 2’-deoxyadenosine to 
2’-deoxyinosine using bovine adenosine-deaminase.17 A DMTr group is installed on 
the 5’-hydroxide, so that the 3’-hydroxide can be selectively protected by TBDPS 
group in DMF. The 5’ DMTr group is subsequently removed under acidic condition to 
form compound 3.11. Treatment with Dess-Martin Periodinane failed to produce the 
aldehyde product 3.12. Instead, a Corey-Kim oxidation was used to give the desired 
product with an increased yield. Then a Wittig reaction gave the terminal olefin 3.13. 
Finally, hydroboration with 9-BBN gave us the 5’ extended 2’-deoxyinosine 3.14. 
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Scheme 3.2 Synthesis of 5’ extended 2’-deoxyinosine, work with Chris Theile 
At this point, the challenge was to convert inosine base back to adenosine. While 
most of the current literature suggests converting inosine to 6-chloropurine first would 
be a promising route,18,19 we found that the chlorinating conditions are too harsh and 
can lead to depurination. Eric Hadter in our group is currently working on the 
continuation of this synthetic route. 
Other synthetic methods are being explored at the same time. Described in 
1968,20 Etzold et al. successfully synthesized 5’ extended dT by converting 5’ 
hydroxide to cyanide (Scheme 3). Hydrogenation, then provide the 5’ extended amine, 
which could then transformed into hydroxide 3.19. 
 
Scheme 3.3 Synthesis of 5’ extended dT by Etzold et al.20 
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Our designed synthesis attempted to simplify this route. After achieving the 
cyanide product, hydrolysis could be used to obtain the 5’ extended hydroxide 
(Scheme 4). First, protecting groups were installed on the exocyclic amine, and 3’ 
hydroxyl groups. Tosyl group was installed on the 5’-OH in pyridine, then directly 
substituted by cyanide in DMF to yield compound 3.21. Unfortunately, basic 
hydrolysis with NaOH in EtOH resulted in depurination. Attempting to take off the 
benzoyl protecting group and use a mild acidic hydrolysis condition didn’t help with 
the problem. We concluded that the adenosine nucleobase is vulnerable to 
depurination under both basic and acidic conditions. 
 
Scheme 3.4 Attempted synthesis of 5’ extended dA through cyanide hydrolysis 
Since depurination has always been the primary problem, and the 6-amine on 
adenosine can become problematic during the synthesis, our current efforts have been 
devoted to the 5’ extension of only the pentose sugar first. At that point, we can then 
attach any nucleobase needed at the anomeric carbon. Our first attempt was to 
synthesize a pentose sugar with a 5-cyanide which could be subsequently hydrolyzed 
to a carboxylic acid. 
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Scheme 3.5 Attempted synthesis of 5’ extended pentose sugar through cyanide hydrolysis 
First, D-deoxyribose 3.25 was cyclized under acidic condition in MeOH and a 
tosyl group was installed on the 5’ hydroxide in an overall yield of 62% over two 
steps. Then, iodide substitution in acetone provided compound 3.28 in 90% yield. 
However, the substitution of 5’-iodo group using KCN in presence of 18-crown-6 was 
unsuccessful.  
 
Scheme 3.6 Another possible route towards the synthesis of 5’ extended pentose sugar 
The route we are following now is shown above in scheme 3.6. D-deoxyribose 
3.25 was cyclized under acidic condition in MeOH. Then three standard protecting 
group reactions were performed on the cyclized sugar ring to protect 3’ hydroxyl with 
TBDPS group, compound 3.31. Further oxidation and Wittig reactions need to be 
carried out before hydroboration with 9-BBN could yield the 5’ extended pentose 
sugar. 
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3.3 Work Towards the Synthesis of 3’ Extended 2’-deoxythymidine 
As discussed above in figure 3.3, 3’ extended dT also needs to be synthesized 
and incorporated into oligonucleotide as dA*-dT* base pairs in order to compensate 
for the 5’ distortion. While thymidine bases are more stable than adenosine bases 
during most reaction conditions, the stereo center at 3’ position provides another 
synthetic challenge. The route we followed in the synthesis of 5’ extended dT, the 
oxidation, Wittig and hydroboration protocols, cannot succeed in the task of installing 
the extra methylene group at 3’ position with the correct stereo chemistry. As 
illustrated in figure 3.5, after the Wittig reaction, the 3’ double bond is co-planar with 
the pentose sugar ring. Since the steric hindrance is bigger on the upper side of the 
ring, the boron complex would presumably bind the double bond from below the ring, 
pushing the extra methylene group upwards. After the oxidation, the hydroxide 
formed would be on the same side of the ring with the nucleobase, which would not 
correspond to the erythro configuration we desire. 
 
Figure 3.5 Stereo chemistry illustration of hydroboration-oxidation at 3’ position 
Although the synthesis of 3’ extended dT has been published previously,15,21,22 
most of these procedures use radical reactions to attach the extra methylene group, 
resulting in a mixture of two stereoisomers. However, in Sanghvi’s procedure,22 a 
high selectivity for the erythro configuration was achieved. The procedure was 
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followed in order to produce 3’ extended dT. 
 
 
Scheme 3.7 Synthesis of 3’ extended dT by Sanghvi et al. 
The 5’-hydroxyl of native dT 3.1 was first selectively protected by TBDPS group 
in DMF, then a phenoxythiocarbonyl group was installed on the 3’-hydroxyl in 
Benzene. The radical addition reaction was performed to yield compound 3.37. 
However, the yield was low and the impurity carried on from the previous step made 
purification of the product difficult. Further attempts to produce reagent 3.41 in a 
large amount failed. Although this procedure could give high stereo selectivity, the 
reactions are hard to carry out and the yields were low. 
Inspired by Koth et al,23 we designed the synthetic route in scheme 3.8. After the 
5’-hydroxyl was protected using TBSCl in DMF, methanesulfonyl group was installed 
on 3’ hydroxyl in pyridine. Refluxing compound 3.43 in EtOH in the presence of TEA 
produced the 2-3’ oxygen bridged compound 3.44 in high yield. We were hoping that 
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with the oxygen bridge blocking the space above the ring, a cyanide group could do 
the nucleophilic attack from below the ring, and give us high stereoselectivity. 
Unfortunately, potassium cyanide was not nucleophilic enough for this transformation 
and we could only isolate starting material from the reaction. 
 
Scheme 3.8 Attempted synthesis of 3’ extended dT. 
One disadvantage to the route shown above is that the oxygen bridge can only be 
formed using pyrimidine bases. We are now looking for a more generalized route for 
all four nucleosides. Similar to the strategy used for 5’ extensions, we want to do the 3’ 
extension on the pentose sugar first, before we attach a nucleobases to the anomeric 
carbon.24,25 
This synthesis began with isopropylidne protection of D-xylose. The resulting 
product was partially hydrolyzed under acidic conditions to yield 1’,2’-isopropylidene 
protected sugar 3.47. Silyl protection group TBDPS was installed on 5’ before an 
oxidation reaction with chromium trioxide in DCM provided the compound 3.49. We 
have only made it to this point in this particular route towards the synthesis of 3’ 
extended dT. We still need to perform a Wittig reaction to get the 3’ olefin 3.50. Since the 
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steric hindrance below the ring now appears to be probably larger, we anticipate that 
most of the boron complex would bind the double bond from above the ring, and yield 
3.51 as the major product. Further protecting group manipulations need to be 
performed before we install a nucleobase onto the C1’. In the last step, the 
2’-hydroxyl will be removed using standard procedure.25 
 
Scheme 3.9 Current synthesis of 3’ extended dT 
 
3.4 Future directions 
Our current goal is to synthesis both 5’ extended dA and 3’ extended dT. Both 
synthetic routes deal with the extension of pentose sugar first, so hopefully, the 
extension of any of the four nucleosides can be achieved using the generalized 
method. 
We are eager to see the effect of incorporating 5’ extended dT*-dA* base pairs. 
Then in order to compensate the distortion caused by 5’-overhang, base pairs of 5’ 
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extended dA and 3’ extended dT will be incorporated. Lastly, a duplex of all modified 
nucleotides (5’ extended dA and 3’ extended dT) will be made, and we expect that a 
new helical structure will form. 
 
3.5 Experimental Procedures 
Chemicals were purchased from Sigma-Aldrich, Acros, Oakwood, Chem-Impex, 
and Fisher. Anhydrous tetrahydrofuran (THF), diethyl ether (Et2O), 
N,N-dimethylformamide (DMF), pyridine (pyr), acetonitrile (MeCN), and 
dichloromethane (DCM) were HPLC grade and further purified by passing through 
activated alumina columns. Anhydrous ethanol (reagent alcohol) was purchased from 
Sigma-Aldrich and used directly. Anhydrous methanol was distilled over magnesium 
and iodide prior to use. Silica gel (60 Å, particle size 40-63 μm) was used for flash 
chromatography and TLCs with F-254 Indicator were visualized by 260nm UV light 
and stained by 10% sulfuric acid. NMR spectra were taken by Varian VNMRS400, 
VNMRS500, or INOVA 500 instruments and calibrated using residual undeuterated 
solvent (CDCl3: δ H = 7.24 ppm, δ C = 77.23 ppm, DMSO-d6: δ H = 2.50 ppm, δ C = 
39.51 ppm, Methanol-d4: δ H=3.31 ppm, δ C = 49.15 ppm). Abbreviations of 
multiplicities were designated as follow: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet. High-resolution mass spectra (HRMS) were recorded on a 
Waters LCT or JEOL AccuTOF 201 mass spectrometer using ESI (electrospray 
ionization) or DART (direct analysis in real time). 
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Compound 3.13  
N-chlorosuccinimide (857 mg, 6.42 mmol) was dissolved in DCM (15 mL) and 
cooled to 0℃. Dimethyl sulfide (2.36 mL, 32.10 mmol) was added to the reaction 
mixture. The reaction was cooled to -78℃ and stirred for 1 hour. A solution of 
compound 3.11 (524 mg, 1.07 mmol) in DCM (10 mL) was added. The reaction was 
continue stirred at -78℃ for 3 hours before TEA (3.0 mL, 21.4 mmol) was added and 
stirring continued at -78℃ for an additional hour. Then the reaction is warmed to 
room temperature, and diluted with DCM (10 mL) and MeOH (5 mL). The mixture 
was then washed with 1% aqueous HCl and brine before being dried over sodium 
sulfate and concentrated under reduced pressure to yield compound 3.12. The crude 
was found pure enough and was carried on to next reaction. 
MePPh3Br (1.55 g, 4.28 mmol) and t-BuOK (423 mg, 3.75 mmol) were 
dissolved in THF (15 mL) and stirred at room temperature for 1 hour. Then a solution 
of crude compound 3.12 in THF (15 mL) was added and stirring continued for 12 
hours. The reaction was quenched with saturated ammonium chloride, and organic 
layer was subsequently washed with brine solution. After dried over Na2SO4 and 
filtered, flash chromatography (15% isopropanol, 85% DCM) was applied to yield 
compound 3.13 (327 mg, 63% over two steps) as a white foam. 1H NMR (500MHz, 
CDCl3) δ 8.04 (s, 1H), 7.83 (s, 1H), 7.43 (m, 4H) 7.38 (m, 6H), 6.45 (t, J=6.5Hz, 1H), 
5.62 (m, 1H), 5.10 (t, J=3.0Hz, 1H), 5.05 (t, J=2.0Hz, 1H), 4.46 (m, 1H), 4.40 (dt, 
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J=4.8, 3.2Hz, 1H), 2.45 (m, 2H), 1.09 (s, 9H). 13C NMR (100MHz, CDCl3), δ 159.3, 
148.9, 145.1, 138.6, 136.0, 135.9, 135.4, 133.3, 133.2, 130.4, 130.3, 128.1, 128.1, 
125.4, 117.9, 88.5, 84.8, 40.1, 27.1, 19.3. HRMS (DART) Calcd. for C27H31N4O3Si 
487.2160; Found, 487.2294. 
 
Compound 3.14  
Compound 3.13 (166 mg, 0.34 mmol) was dissolved in THF (3 mL) and cooled 
to 0℃. A 0.5M solution of 9-BBN in THF (2.72 mL, 1.36 mmol) was added. The 
reaction was stirred at room temperature for 3 hours before quenched with 1M NaOH 
(5 mL) and 30% H2O2 (0.8 mL). The organic layer was separated and washed with 
brine solution. After dried over Na2SO4 and filtered, flash chromatography (15% 
isopropanol, 85% DCM) was applied to yield compound 3.14 as a white foam (70 mg, 
41%). 1H NMR (500 MHz, CDCl3) δ 12.73 (s, 1H), 8.04 (s, 1H), 7.80 (s, 1H), 
7.67-7.63 (m, 4H), 7.50-7.33 (m, 6H), 6.33 (t, J = 6.6 Hz, 1H), 4.42 (dt, J = 5.7, 3.7 
Hz, 1H), 4.15 (td, J = 6.5, 3.5 Hz, 1H), 3.60-3.49 (m, 2H), 2.54-2.47 (m, 1H), 
2.47-2.40 (m, 1H), 1.61 (q, J = 6.1 Hz, 2H), 1.09 (s, 9H). HRMS (DART) Calcd. for 
C27H33N4O4Si 505.2266; Found, 505.2352 
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Compound 3.26  
Acetyl chloride (1.7 mL) was added to MeOH (100 mL) to make 1% methanolic 
hydrogen chloride solution. 2-deoxy-D-ribose (1.0 g, 7.45 mmol) was dissolved in 
MeOH (12 mL). 1% methanolic hydrogen chloride (2 mL) was added to reaction flask. 
The reaction was stirred at room temperature for 0.5 hour before neutralized by solid 
NaHCO3. The reaction mixture was filtered, solvent removed under reduced pressure. 
And flash chromatography (10% MeOH, 90% DCM) was applied to yield compound 
3.26 (729 mg, 66%). Two isomers at C1’ were formed. 13C NMR (100 MHz, CDCl3), 
δ 105.76/105.71, 87.74/87.61, 73.03/72.32, 63.75/63.32, 55.65/55.09, 42.76/41.77. 
HRMS (DART) Calcd. for C5H9O3 177.0546; Found, 177.0593. 
 
Compound 3.48  
Compound 3.47 (2.72 g, 14.3 mmol) and imidazole (0.86 g, 14.3 mmol) was 
dissolved in DMF (50 mL) and stirred for 5 minutes. Then TBDPSCl (3.7 mL, 14.3 
mmol) was added. Reaction was stirred at room temperature for 12 hours. After the 
reaction, solvent was removed under reduced pressure and the crude was applied to 
flash chromatography (20% EtOAc, 80% Hexanes) to yield compound 3.48 as clear 
oil (5.45 g, 89%). 1H NMR (500 MHz, CDCl3) δ 7.64 (m, 4H), 7.38 (m, 6H), 5.98 (d, 
J =3.5 Hz, 1H), 4.52 (d, J =3.5 Hz, 1H), 4.35 (t, J =2.5 Hz, 1H), 4.11 (t, J =3.5 Hz, 
1H), 4.01-4.09 (m, 2H), 1.45 (s, 3H), 1.31 (s, 3H), 1.03 (s, 9H). HRMS (DART) 
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Calcd. for C24H33O5Si 428.2019; Found, 428.2533. 
 
Compound 3.49  
Compound 3.48 (676 mg, 1.58 mmol) was dissolved in DCM (3 mL), and was 
added into previously prepared DCM solution (5 mL) containing CrO3-Pyridine-Ac2O 
(315 mg, 3.15 mmol: 0.5 mL: 0.3 mL). The reaction was stirred at room temperature 
for 4 hours, and then added dropwise to ethyl acetate (20 mL) while stirring. The 
precipitate was filtered off and the filtrate was concentrated. The residue was purified 
by flash chromatography (30% EtOAc, 70% Hexanes) to yield white solid compound 
3.49 (479 mg, 71%). 1H NMR (500 MHz, CDCl3) δ 7.66 (m, 4H), 7.39 (m, 6H), 6.23 
(d, J =4.5 Hz, 1H), 4.40 (d, J =4.5 Hz, 1H), 4.37 (m, 1H), 3.89 (m, 2H), 1.46 (s, 3H), 
1.45 (s, 3H), 0.99 (s, 9H). 13C NMR (100 MHz, CDCl3), δ 135.72, 130.21, 130.11, 
129.79, 128.10, 127.88, 114.44, 103.99, 81.72, 77.35, 64.89, 27.94, 27.44, 26.99, 
26.90. HRMS (DART) Calcd. for C24H31O5Si 427.1935; Found, 427.1957. 
 
  
  90 
 
3.6 1H and 13C NMR Spectra 
Compound 3.13 1H NMR (500 MHz, CDCl3) 
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Compound 3.13 13C NMR (100 MHz, CDCl3) 
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Compound 3.14 1H NMR (500 MHz, CDCl3) 
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Compound 3.26 1H NMR (500 MHz, CDCl3) 
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Compound 3.26 13C NMR (100 MHz, CDCl3) 
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Compound 3.48 1H NMR (500 MHz, CDCl3) 
 
 
  96 
 
Compound 3.49 1H NMR (500 MHz, CDCl3) 
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Compound 3.49 13C NMR (100 MHz, CDCl3) 
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